Could mesenchymal stromal cells have a role in childhood autoimmune diseases?

References

• Aggarwal S, Pittenger MF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815–22
   PubMed Web of Science ®Google Scholar
• Allison M. (2009). Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol, 27, 966–7
   PubMed Web of Science ®Google Scholar
• Angoulvant D, Clerc A, Benchalal S, et al. (2004). Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology, 41, 469–76
   PubMed Web of Science ®Google Scholar
• Asano M, Toda M, Sakaguchi N, Sakaguchi S. (1996). Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med, 184, 387–96
   PubMed Web of Science ®Google Scholar
• Augello A, Tasso R, Negrini SM, et al. (2007). Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum, 56, 1175–86
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. (2007). Management of acute graft-versus-host disease. Br J Haematol, 137, 87–98
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Locatelli F, Egeler RM. (2008). Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow Transplant, 42, S60–6
   Google Scholar
• Ball LM, Bernardo ME, Roelofs H, et al. (2007). Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood, 110, 2764–7
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 30, 42–8
   PubMed Web of Science ®Google Scholar
• Ben-Ami E, Berrih-Aknin S, Miller A. (2011). Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev, 10, 410–15
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Fibbe WE. (2012). Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci, 1266, 107–17
   PubMed Web of Science ®Google Scholar
• Bocelli-Tyndall C, Bracci L, Spagnoli G, et al. (2007). Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology, 46, 403–8
   PubMed Web of Science ®Google Scholar
• Brinkman DM, De Kleer IM, Ten Cate R, et al. (2007). Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: Long-term follow-up of a prospective clinical trial. Arthritis Rheum, 56, 2410–21
   PubMed Web of Science ®Google Scholar
• Brunner HI, Gladman DD, Ibañez D, et al. (2008). Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum, 58, 556–62
   PubMed Web of Science ®Google Scholar
• Calkoen FG, Brinkman DM, Vervat C, et al. (2013). Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses. Cytotherapy, 15, 280–91
   Google Scholar
• Carrion F, Nova E, Ruiz C, et al. (2010). Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus, 19, 317–22
   PubMed Web of Science ®Google Scholar
• Chabannes D, Hill M, Merieau E, et al. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood, 110, 3691–4
   PubMed Web of Science ®Google Scholar
• Chang JW, Hung SP, Wu HH, et al. (2011). Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant, 20, 245–57
   PubMed Web of Science ®Google Scholar
• Chen J, Wang Y, Kunkel G, et al. (2005). Use of CD34+ autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus. Clin Rheumatol, 24, 464–8
   Google Scholar
• Choumerianou DM, Dimitriou H, Perdikogianni C, et al. (2008). Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif, 41, 909–22
   PubMed Web of Science ®Google Scholar
• Constantin G, Marconi S, Rossi B, et al. (2009). Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells, 27, 2624–35
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107, 367–72
   PubMed Web of Science ®Google Scholar
• Couriel D, Caldera H, Champlin R, Komanduri K. (2004). Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. Cancer, 101, 1936–46
   PubMed Web of Science ®Google Scholar
• Crop MJ, Korevaar SS, de Kuiper R, et al. (2011). Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. Cell Transplant, 20, 1547–59
   Google Scholar
• Dazzi F, Horwood NJ. (2007). Potential of mesenchymal stem cell therapy. Curr Opin Oncol, 19, 650–5
   PubMed Web of Science ®Google Scholar
• De Kleer IM, Brinkman DM, Ferster A, et al. (2004). Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: Analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis, 63, 1318–26
   PubMed Web of Science ®Google Scholar
• De Kleer I, Vastert B, Klein M, et al. (2006). Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood, 107, 1696–702
   PubMed Web of Science ®Google Scholar
• Descloux E, Durieu I, Cochat P, et al. (2009). Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology, 48, 779–84
   Google Scholar
• Di Ianni M, Del Papa B, De Ioanni M, et al. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol, 36, 309–18
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838–43
   PubMed Web of Science ®Google Scholar
• Dimitriou H, Linardakis E, Martimianaki G, et al. (2008). Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases. Cytotherapy, 10, 125–33
   PubMed Web of Science ®Google Scholar
• Dimitriou H, Perdikogianni Ch, Martimianaki G, et al. (2009). Are mesenchymal stromal cells from children resistant to apoptosis? Cell Prolif, 42, 276–83
   PubMedGoogle Scholar
• Djouad F, Bouffi C, Ghannam S, et al. (2009). Mesenchymal stem cells: Innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol, 5, 392–9
   PubMed Web of Science ®Google Scholar
• Djouad F, Fritz V, Apparailly F, et al. (2005). Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum, 52, 1595–603
   PubMed Web of Science ®Google Scholar
• El-Badri NS, Hakki A, Ferrari A, et al. (2008). Autoimmune disease: Is it a disorder of the microenvironment?. Immunol Res, 41, 79–86
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A, et al. (2010). Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 95, 284–92
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. (1966). Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol, 16, 381–90
   PubMedGoogle Scholar
• González MA, Gonzalez-Rey E, Rico L, et al. (2009). Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum, 60, 1006–19
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Gonzalez MA, Varela N, et al. (2010). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis, 69, 241–8
   PubMed Web of Science ®Google Scholar
• Gu Z, Akiyama K, Ma X, et al. (2010). Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus, 19, 1502–14
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Gordon PL, et al. (2001). Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfect. Blood, 97, 1227–31
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Gordon PL, Koo WK, et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA, 99, 8932–7
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Le Blanc K, Dominici M, et al. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 7, 393–5
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Imundo LF, Avitabile C, et al. (2011). Early versus later onset childhood-onset systemic lupus erythematosus: Clinical features, treatment and outcome. Lupus, 20, 952–9
   PubMed Web of Science ®Google Scholar
• Illei GG, Cervera R, Burt RK, et al. (2011). Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis, 70, 2071–4
   PubMed Web of Science ®Google Scholar
• Jarvinen L, Badri L, Wettlaufer S, et al. (2008). Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol, 181, 4389–96
   PubMed Web of Science ®Google Scholar
• Jayne D, Passweg J, Marmont A, et al. (2004). Autologous stem cell transplantation for systemic lupus erythematosus. Lupus, 13, 168–76
   PubMed Web of Science ®Google Scholar
• Jiang XX, Zhang Y, Liu B, et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105, 4120–6
   PubMed Web of Science ®Google Scholar
• Jones BJ, McTaggart SJ. (2008). Immunosuppression by mesenchymal stromal cells: From culture to clinic. Exp Hematol, 36, 733–41
   PubMed Web of Science ®Google Scholar
• Kastrinaki MC, Sidiropoulos P, Roche S, et al. (2008). Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis, 67, 741–9
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Robinson S. (2011). Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease. Front Oncol, 1, 16, 1--8
   Google Scholar
• Kemp KC, Hows J, Donaldson C. (2005). Bone marrow-derived mesenchymal stem cells. Leuk & Lymph, 46, 1531–44
   PubMed Web of Science ®Google Scholar
• Koç ON, Day J, Nieder M, et al. (2002). Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant, 30, 215–22
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, et al. (2004). Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T-cells to their cognate peptide. Blood, 101, 3722–9
   Google Scholar
• Kurtzberg J, Prasad V, Grimley MS, et al. (2010). Allogeneic human mesenchymal stem cell therapy (PROCHYMAL) as a rescue agent for severe treatment resistant GVHD in pediatric patients. Biol Blood Marrow Transplant, 16, S169
   Google Scholar
• Larghero J, Farge D, Braccini A, et al. (2008). Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis, 67, 443–9
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371, 1579--86
   Google Scholar
• Le Blanc K, Rasmusson I, Goetherstroem G, et al. (2004a). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol, 60, 307–15
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, et al. (2004b). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 1439–41
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med, 262, 509–25
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, et al. (2003). Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the Major Histocompatibility Complex. Scand J Immunol, 56, 11–20
   Google Scholar
• Lee SJ. (2010). Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol, 23, 529–35
   PubMed Web of Science ®Google Scholar
• Liang J, Li X, Zhang H, et al. (2012). Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol, 31, 157–61
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang H, Hua B, et al. (2010). Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis, 69, 1423–9
   PubMed Web of Science ®Google Scholar
• Liu Y, Mu R, Wang S, et al. (2010). Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther, 12, R210, 1--13
   Google Scholar
• Lucchini G, Introna M, Dander E, et al. (2010). Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant, 16, 1293–301
   PubMed Web of Science ®Google Scholar
• MacDonald GI, Augello A, De Bari C. (2011). Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum, 63, 2547–57
   PubMed Web of Science ®Google Scholar
• Martin B, Uberti J, Soiffer R, et al. (2010). Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant, 16, 169–70
   Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, et al. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103, 4619–21
   PubMed Web of Science ®Google Scholar
• Mina R, Brunner HI. (2010). Pediatric lupus–are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. Rheum Dis Clin North Am, 36, 53–80
   PubMed Web of Science ®Google Scholar
• Nasef A, Mathieu N, Chapel A, et al. (2007). Immunosuppressive effects of mesenchymal stem cells: Involvement of HLA-G. Transplantation, 84, 231–7
   PubMed Web of Science ®Google Scholar
• Nasef A, Mazurier C, Bouchet S, et al. (2008). Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol, 253, 16–22
   PubMed Web of Science ®Google Scholar
• Nie Y, Lau C, Lie A, et al. (2010). Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus, 19, 850–9
   PubMed Web of Science ®Google Scholar
• Otsuru S, Gordon PL, Shimono K, et al. (2012). Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood, 120, 1933–41
   PubMedGoogle Scholar
• Park MJ, Park HS, Cho ML, et al. (2011). Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum, 63, 1668–80
   PubMed Web of Science ®Google Scholar
• Prakken B, Albani S, Martini A. (2011). Juvenile idiopathic arthritis. Lancet, 377, 2138–49
   PubMed Web of Science ®Google Scholar
• Prasad VK, Lucas KG, Kleiner GI, et al. (2011). Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant, 17, 534–41
   PubMed Web of Science ®Google Scholar
• Prevosto C, Zancolli M, Canevali P, et al. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica, 92, 881–8
   PubMed Web of Science ®Google Scholar
• Rasmusson I. (2006). Immune modulation by mesenchymal stem cells. Exp Cell Res, 312, 2169–79
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Ringden O, Sundberg B, Le Blanc K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76, 1208–13
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol, 65, 336–43
   PubMed Web of Science ®Google Scholar
• Ren G, Zhang L, Zhao X, et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2, 141–50
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Battaglia M. (2007). Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol, 7, 585–98
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Oh I, et al. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109, 228–34
   PubMed Web of Science ®Google Scholar
• Schurgers E, Kelchtermans H, Mitera T, et al. (2010). Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther, 12, R31, 1--11
   Google Scholar
• Selmani Z, Naji A, Zidi I, et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26, 212–22
   PubMed Web of Science ®Google Scholar
• Siegel G, Schäfer R, Dazzi F. (2009). The immunosuppressive properties of mesenchymal stem cells. Transplantation, 87, 45–9
   PubMed Web of Science ®Google Scholar
• Snowden JA, Passweg J, Moore JJ, et al. (2004). Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J Rheumatol, 31, 482–8
   PubMed Web of Science ®Google Scholar
• Song XN, Lv HY, Sun LX, et al. (2011). Autologous stem cell transplantation for systemic lupus erythematosus: Report of efficacy and safety at 7 years of follow-up in 17 patients. Transplant Proc, 43, 1924–47
   Google Scholar
• Sotiropoulou PA, Perez SA, Gritzapis AD, et al. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24, 74–85
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Abdelrazik H, et al. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111, 1327–33
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Becchetti S, et al. (2006). Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107, 1484–90
   PubMed Web of Science ®Google Scholar
• Sun L, Akiyama K, Zhang H, et al. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells, 27, 1421–32
   PubMed Web of Science ®Google Scholar
• Sun L, Wang D, Liang J, et al. (2010). Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum, 62, 2467–75
   PubMed Web of Science ®Google Scholar
• Sun LY, Zhang HY, Feng XB, et al. (2007). Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus, 16, 121–8
   PubMed Web of Science ®Google Scholar
• Traggiai E, Volpi S, Schena F, et al. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 26, 562–9
   PubMed Web of Science ®Google Scholar
• Tse WT, Pendleton JD, Beyer WM, et al. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation, 75, 389–97
   PubMed Web of Science ®Google Scholar
• Tyndall A. (2009). Cellular therapy of systemic lupus erythematosus. Lupus, 18, 387–93
   Google Scholar
• Tyndall A. (2011). Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Book, 2011, 280–4 . doi: 10.1182/asheducation-2011.1.280
   Google Scholar
• Uccelli A, Mancardi G, Chiesa S. (2008). Is there a role for mesenchymal stem cells in autoimmune diseases? Autoimmunity, 41, 592–5
   PubMed Web of Science ®Google Scholar
• Uccelli A, Pistoia V, Moretta L. (2007). Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol, 28, 219–26
   PubMed Web of Science ®Google Scholar
• von Bonin M, Stölzel F, Goedecke A, et al. (2009). Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant, 43, 245–51
   PubMed Web of Science ®Google Scholar
• Weng JY, Du X, Geng SX, et al. (2010). Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant, 45, 1732–40
   PubMed Web of Science ®Google Scholar
• Wernicke CM, Grunewald TG, Juenger H, et al. (2011). Mesenchymal stromal cells for treatment of steroid-refractory GvHD: A review of the literature and two pediatric cases. Int Arch Med, 4, 27, 1--9
   Google Scholar
• Whyte MP, Kurtzberg J, McAlister WH, et al. (2003). Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res, 18, 624–36
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, van Rooijen EM, Tewarie R, et al. (2008). Current perspectives of autologous stem cell transplantation for severe Juvenile Idiopathic Arthritis. Autoimmunity, 41, 632–8
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, van Royen A, Bierings M, et al. (1999). Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet, 353, 550–3
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, Sanders EA, Kamphuis SS, et al. (2001). Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus. Arthritis Rheum, 44, 728–31
   PubMed Web of Science ®Google Scholar
• Wulffraat NM, Vastert B, Tyndall A. (2005). Treatment of refractory autoimmune diseases with autologous stem cell transplantation: Focus on juvenile idiopathic arthritis. Bone Marrow Transplant, 35, S27–9
   Google Scholar
• Yang SH, Park MJ, Yoon IH, et al. (2009). Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med, 41, 315–24
   PubMed Web of Science ®Google Scholar
• Youd M, Blickarz C, Woodworth L, et al. (2010). Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol, 161, 176–86
   PubMed Web of Science ®Google Scholar
• Zappia E, Casazza S, Pedemonte E, et al. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 106, 1755–61
   PubMed Web of Science ®Google Scholar
• Zheng ZH, Li XY, Ding J, et al. (2008). Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology, 47, 22–30
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhang H, Jin O, et al. (2008). Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol, 5, 417–24
   PubMed Web of Science ®Google Scholar